{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32","upperLimit":"40","value":"40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Median overall survival after first peripheral blood stem cell transplant (PBSCT).","dispersionType":"95% Confidence Interval","groups":[{"description":"bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous peripheral blood stem cell transplant\n\nBortezomib : the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant\n\nPBSCT : PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)\n\nMelphalan : Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes","id":"OG000","title":"Autologous PBSCT"}],"paramType":"MEDIAN","populationDescription":"All evaluable participants","reportingStatus":"POSTED","timeFrame":"40 months post transplant","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}